300 related articles for article (PubMed ID: 27737810)
1. Development of controlled-release cisplatin dry powders for inhalation against lung cancers.
Levet V; Rosière R; Merlos R; Fusaro L; Berger G; Amighi K; Wauthoz N
Int J Pharm; 2016 Dec; 515(1-2):209-220. PubMed ID: 27737810
[TBL] [Abstract][Full Text] [Related]
2. Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties.
Levet V; Merlos R; Rosière R; Amighi K; Wauthoz N
Int J Pharm; 2017 Jan; 517(1-2):359-372. PubMed ID: 28007545
[TBL] [Abstract][Full Text] [Related]
3. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
Razavi Rohani SS; Abnous K; Tafaghodi M
Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
[TBL] [Abstract][Full Text] [Related]
5. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
6. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
7. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
Yu J; Chan HK; Gengenbach T; Denman JA
Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
[TBL] [Abstract][Full Text] [Related]
8. The combination of an innovative dry powder for inhalation and a standard cisplatin-based chemotherapy in view of therapeutic intensification against lung tumours.
Chraibi S; Rosière R; Larbanoix L; Gérard P; Hennia I; Laurent S; Vermeersch M; Amighi K; Wauthoz N
Eur J Pharm Biopharm; 2021 Jul; 164():93-104. PubMed ID: 33957225
[TBL] [Abstract][Full Text] [Related]
9. Lecithin/TPGS-based spray-dried self-microemulsifying drug delivery systems: In vitro pulmonary deposition and cytotoxicity.
Ishak RA; Osman R
Int J Pharm; 2015 May; 485(1-2):249-60. PubMed ID: 25772421
[TBL] [Abstract][Full Text] [Related]
10. Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension.
Shahin HI; Vinjamuri BP; Mahmoud AA; Shamma RN; Mansour SM; Ammar HO; Ghorab MM; Chougule MB; Chablani L
J Control Release; 2019 May; 302():126-139. PubMed ID: 30940497
[TBL] [Abstract][Full Text] [Related]
11. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
12. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.
Meenach SA; Anderson KW; Zach Hilt J; McGarry RC; Mansour HM
Eur J Pharm Sci; 2013 Jul; 49(4):699-711. PubMed ID: 23707466
[TBL] [Abstract][Full Text] [Related]
13. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
14. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
[TBL] [Abstract][Full Text] [Related]
15. Aerosolizable gold nano-in-micro dry powder formulations for theragnosis and lung delivery.
Silva AS; Sousa AM; Cabral RP; Silva MC; Costa C; Miguel SP; Bonifácio VDB; Casimiro T; Correia IJ; Aguiar-Ricardo A
Int J Pharm; 2017 Mar; 519(1-2):240-249. PubMed ID: 28111281
[TBL] [Abstract][Full Text] [Related]
16. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
[TBL] [Abstract][Full Text] [Related]
17. New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy.
Rosière R; Gelbcke M; Mathieu V; Van Antwerpen P; Amighi K; Wauthoz N
Int J Oncol; 2015 Sep; 47(3):1131-42. PubMed ID: 26201404
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment.
Wauthoz N; Deleuze P; Saumet A; Duret C; Kiss R; Amighi K
Pharm Res; 2011 Apr; 28(4):762-75. PubMed ID: 21116692
[TBL] [Abstract][Full Text] [Related]
19. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections.
Matinkhoo S; Lynch KH; Dennis JJ; Finlay WH; Vehring R
J Pharm Sci; 2011 Dec; 100(12):5197-205. PubMed ID: 22020816
[TBL] [Abstract][Full Text] [Related]
20. Novel dry powder inhalation system based on dispersion of lyophilisates.
Claus S; Schoenbrodt T; Weiler C; Friess W
Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
